Quick answers
- What is Lidocaine hydrochloride anhydrous and dextrose monohydrate used for?
- The FDA-approved label (Lidocaine Hydrochloride and Dextrose, ProPharma Distribution, January 19, 2026) says: “Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Lidocaine hydrochloride anhydrous and dextrose monohydrate have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Lidocaine hydrochloride anhydrous and dextrose monohydrate?
- The FDA drug shortage list shows “Current shortage” for a product of this medicine (updated October 19, 2026). Ask your pharmacist about alternatives.
- Has Lidocaine hydrochloride anhydrous and dextrose monohydrate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Lidocaine hydrochloride anhydrous and dextrose monohydrate?
- 2 companies list prescription products of Lidocaine hydrochloride anhydrous and dextrose monohydrate in the FDA NDC Directory, including B. Braun Medical Inc. and ProPharma Distribution.
What Lidocaine hydrochloride anhydrous and dextrose monohydrate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.
— FDA label: Lidocaine Hydrochloride and Dextrose, ProPharma Distribution, effective January 19, 2026. Read the full label on DailyMed →
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 3 in the FDA NDC Directory |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- B. Braun Medical Inc.2 products
- ProPharma Distribution1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA019830 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER | B Braun | April 8, 1992 | 11, latest May 19, 2020 2020: Labeling · 2017: Manufacturing (CMC) · 2014: Manufacturing (CMC) |
Shortage status
Current shortage · updated October 19, 2026 · first posted October 25, 2017
| Product | Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10) |
|---|---|
| Availability | Available |
| Company | B. Braun Medical Inc. |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1737723, 1737742, 1737744 |
|---|---|
| SPL set ID of the quoted label | 48c0ee87-f722-1a71-e063-6394a90a72d1 |
| FDA labels (SPL) | 2 |
| FDA applications | NDA019830 |
| Active ingredients (FDA) | DEXTROSE MONOHYDRATE / LIDOCAINE HYDROCHLORIDE ANHYDROUS |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Lidocaine Hydrochloride and Dextrose, ProPharma Distribution, effective January 19, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →